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Glial proliferation and activation are associated with disease pro-
gression in amyotrophic lateral sclerosis (ALS) and frontotemporal
lobar dementia. In this study, we describe a unique platform to ad-
dress the question of cell autonomy in transactive response DNA-
binding protein (TDP-43) proteinopathies. We generated functional
astroglia fromhuman inducedpluripotent stem cells carrying anALS-
causing TDP-43 mutation and show that mutant astrocytes exhibit
increased levels of TDP-43, subcellular mislocalization of TDP-43, and
decreased cell survival.We then performed coculture experiments to
evaluate the effects ofM337V astrocytes on the survival ofwild-type
and M337V TDP-43 motor neurons, showing that mutant TDP-43
astrocytes do not adversely affect survival of cocultured neurons.
These observations reveal a signiﬁcant and previously unrecognized
glial cell-autonomous pathological phenotype associated with a
pathogenic mutation in TDP-43 and show that TDP-43 proteinopa-
thies do not display an astrocyte non-cell-autonomous component
in cell culture, as previously described for SOD1 ALS. This study
highlights the utility of induced pluripotent stem cell-based in vitro
disease models to investigate mechanisms of disease in ALS and
other TDP-43 proteinopathies.
glia | motor neuron disease | disease modeling
Transactive response DNA-binding protein (TDP-43) is themajor component of ubiquitinated cytoplasmic and nuclear
inclusions in neurons and astroglia in amyotrophic lateral sclerosis
(ALS) and a subgroup of frontotemporal lobar degeneration
(FTLD-TDP) (1–3). These pathological hallmarks provide a uni-
fying description of a range of conditions deﬁned as TDP-43 pro-
teinopathies (4). At present, >30 mutations in the TDP-43 gene
(TARDBP) have been linked to familial ALS (fALS) (5), strongly
suggesting a causative role for TDP-43 in the pathogenesis of ALS.
Accumulating evidence from experimental systems implicating
non-cell-autonomous mechanisms in ALS has highlighted the im-
portance of the glial cellular environment to motor neuron (MN)
degeneration (1, 3, 6–9). In vivo rodent models of ALS with line-
age-speciﬁc SOD1 expression have particularly inﬂuenced our
understanding of the nonneuronal contribution to disease pro-
gression. Glial expression of mutant SOD1 cannot initiate MN
disease on its own, but is necessary for disease progression (6, 7).
Furthermore, astrogliosis precedes MN degeneration in some an-
imal models and is a dominant feature of all humanALS pathology
(4, 6, 10). Collectively, these observations highlight the need to
better understand the nature of astroglial pathology in ALS.
Combining developmental neurobiological principles of cell fate
determination with human induced pluripotent stem cell (iPSC)
lines derived frompatients carryingALS disease-causingmutations
may provide important insights into astroglia pathology.
We recently generated human MNs from iPSC lines derived
from a fALS patient and demonstrated that the M337V TDP-43
mutation confers cell-autonomous toxicity to MNs (11). Moreover,
quantitative Western blot and immunohistochemical analysis of
M337V neuronal cultures revealed an increase in levels of soluble
and detergent-resistant TDP-43 proteins without any detectable
changes in nuclear TDP-43 immunohistochemistry, implicating cy-
toplasmic misaccumulation of TDP-43 in disease pathogenesis
(11). Given that key features of the TDP-43 proteinopathies
could be detected in iPSC-derived neurons, and noting recent
independent conﬁrmation in multiple patient lines (12), we
addressed the possibility that astroglial TDP-43 pathology
could be investigated by the same approach.
Here we describe the pathological effects of mutant TDP-43 in
isolated functional astrocytes, generated by a direct astrocyte
speciﬁcation protocol from patient-derived M337V iPSC lines.
We then investigate the inﬂuence of mutant astrocytes on neu-
rons to determine whether non-cell-autonomous toxicity can be
detected in cell culture.
Results
Generating Functional Astrocyte Populations from iPSC Lines.
Astroglial populations from two TDP-43 M337V and two con-
trol (CTRL) iPSC lines were derived from neural precursors
(NPCs) (Fig. 1A), generated as described (11). NPCs were cul-
tured in suspension as neurospheres in medium containing epi-
dermal growth factor (EGF) and leukemia inhibitory factor (LIF)
for 4–6 wk. In the absence of ﬁbroblast growth factor 2 (FGF2),
coapplication of EGF and LIF in prolonged culture promoted
astroglial speciﬁcation of NPCs (13, 14) and efﬁciently selected for
neurospheres with a high content of astroglial progenitors. After
this enrichment phase, neurospheres were expanded in EGF- and
FGF2-containing medium before enzymatic dissociation to single
cells. The resulting populations were positive for vimentin and
nuclear factor 1A, two markers of astrocyte progenitor cells
(APCs) (refs. 15 and 16; Fig. 1B), and could be propagated as
a monolayer culture with EGF and FGF2. Less than 30% of cells
in early passage APC cultures were positive for the astrocytic
marker glial ﬁbrillary acidic protein (GFAP). Subsequent differ-
entiation over 14 d in the presence of ciliary neurotrophic factor
(CNTF) increased the proportion of GFAP-positive cells with
>90% of the cells coexpressing the astrocytic markers GFAP and
S100β (Fig. 1 C and D). Fewer than 2% of cells were positive for
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the neuronal marker βIII tubulin, conﬁrming the efﬁciency of this
protocol in generating highly enriched APC populations.
No difference was observed in the efﬁciencies of astrocyte
differentiation in TDP-43M337V and CTRL iPSC lines (Fig. 1F).
The differentiated populations of iPSC-derived astrocytes were pos-
itive for the metabotropic glutamate transporter EAAT1 (Fig. S1)
and could uptake L-glutamate from the medium in a time-dependent
fashion (Fig. 2A). L-glutamate uptake was blocked by the glutamate
transporter inhibitor L-transpyrrolidine-2,4-dicarboxylic acid or by
removing sodium from the medium, consistent with the mechanism
of action of EAAT1. No difference was observed in the L-glutamate
clearance properties ofmutant andCTRLastrocytes (Fig. 2B andC).
We next sought to determine whether the iPSC-derived astro-
cytes promoted the formation of mature synapses. Astrocytes
from either CTRL or mutant iPSC lines were cocultured with
differentiating CTRL iPSC-derived ventral-spinal cord patterned
neurons (11) for a period of 3 wk. Cultures were stained with
antibodies against the presynaptic protein synaptophysin I (PSY)
and the postsynaptic density protein PSD-95 to quantify the
number of mature synapses in cocultures and isolated neuronal
cultures (17–19). No difference between mutant and CTRL
astrocytes was observed in promotion of PSY+/PSD-95+ synaptic
puncta on CTRL neurons (Fig. 2 D and E). Moreover, similar
numbers of PSY+/PSD-95+ synaptic puncta were found in
M337V and WT neurons when cocultured with M337V or WT
astrocytes, suggesting that synaptogenesis is independent of the
genetic background of the neurons and the glia (Fig. 2F). Both
genotypes of iPSC-derived astrocytes exhibited the potential to
propagate calcium waves upon mechanical stimulation. (Fig. 2G
and Movie S1). Calcium waves were also elicited when astrocytes
were stimulated by local application of ATP (Movie S2), as de-
scribed (20–22). This ATP-evoked increase in cytosolic calcium
was abolished by application of 2-aminoethoxydiphenyl borate, an
inhibitor of IP3-dependent calcium release (22) (Movie S3).
These ﬁndings conﬁrm functional equivalence between TDP43
mutant and CTRL astrocytes.
Characterization of TDP-43 in iPSC-Derived Astrocytes. We then
sought to investigate the consequence of M337V mutation on as-
trocyte mRNA expression, protein levels, and subcellular locali-
zation of TDP-43. Quantitative RT-PCR (qRT-PCR) analysis
revealed no signiﬁcant difference in the expression levels of
TARDBP and HDAC6 (which is transcriptionally regulated by
TDP-43 itself; ref. 23) (Fig. 3A). M337V and CTRL cultures also
showed no difference in expression levels of astrocytic markers
GFAP and S100β, further conﬁrming that both genotypes can give
rise to comparable astrocyte populations (Fig. 3A). Having estab-
lished that the level of TDP-43 transcripts do not differ between
M337V and CTRL astrocytes, we investigated whether the mutant
astrocytes exhibit a cellular and biochemical signature (24) similar
to that observed in MN cultures derived from the same iPSC lines
(11). Immunoblot analysis showed that M337V astrocytes have
signiﬁcantly more soluble TDP-43 (Fig. 3 B and C), although they
do not exhibit a corresponding increase in detergent-resistant TDP-
43 (Fig. S2). Cytoplasmic accumulation and mislocalization of
TDP-43 are also hallmarks of TDP-43 proteinopathies (25, 26), and
glial inclusions are recognized in pathological material (27). Den-
sitometric analysis of TDP-43 subcellular localization in iPSC-de-
rived astrocytes by immunolabeling and confocal imaging revealed
that M337V astrocytes exhibit signiﬁcantly higher levels of cyto-
plasmic TDP-43 than CTRL astrocytes (Fig. 3 D and E). In-
terestingly, nuclear levels of TDP-43 in mutant astrocytes did not
differ signiﬁcantly fromCTRLs, as reported forMNs (Fig. 3E) (11).
Fig. 1. Generation of astrocytes from iPSC lines. (A) iPSC-derived neurospheres were enriched for APCs by culturing in EGF/LIF-containing medium for 2–4 wk
and then expanded in EGF/FGF2-containing medium. To obtain monolayer cultures, enriched neurospheres were dissociated by using papain and differ-
entiated with CNTF. (B) APCs in monolayer cultures maintained a homogenous identity and morphology, featuring a high percentage of cells positive for the
glial progenitors markers Vimentin (85.6 ± 2.9% SEM) and NFIA (79.8 ± 1.9% SEM; scale bar: 100 μm.) (C) APC presented 24.6 ± 2.6% SEM cells positive for
GFAP during proliferation in EGF and FGF2; this percentage increased rapidly during the ﬁrst 7 d of CNTF differentiation (84.9 ± 0.5% SEM), reaching a peak
after 14 d (90.8 ± 1.1% SEM; scale bar: 100 μm). (D) Differentiation of monolayer APCs for 14 d in CNTF resulted in a population of astrocytes positive for GFAP
(90.6 ± 0.7% SEM) and S100β (91.9 ± 1.9% SEM) (images represent the same ﬁeld; scale bar: 25 μm.) A few neurons were found in the differentiated cultures
(1.7 ± 0.4% SEM). (E) Representative ﬁeld for a differentiated iPSC-derived astrocytes after 14 d of CNTF differentiation, labeled for GFAP (red) and TuJ1
(green), showing that the protocol gives rise to highly enriched cultures of astrocytes. (Scale bar: 100 μm). (F) M337V and CTRL iPSC lines showed comparable
numbers of GFAP-positive cells postdifferentiation (M337V, 92.3 ± 1.0%; WT, 91.36 ± 1.0%; SEM).
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Ectopic Mutant TDP-43 Expression in CTRL Astrocytes Reproduces
Cellular Phenotype of Patient-Derived M337V Astrocytes. Previous
studies demonstrated that ectopic expression of TDP-43 M337V in
neurons is toxic and that cytoplasmic localization of TDP-43 is in-
dependently associated with an increased risk of death (28). To
determinewhetherM337VTDP-43was similarly toxic to astrocytes,
CTRL iPSC astrocytes were ﬁrst transfected with a plasmid en-
coding either WT or M337V TDP-43 fused to mApple, under the
control of a constitutive promoter (Fig. 4A). Images were then an-
alyzed for survival, localization, and relative expression levels of
exogenous TDP-43 within transfected cells. The transfected astro-
cyte populations were divided in ﬁve different groups based on the
relative expression levels of exogenous TDP-43 (Fig. S3).Within the
different expression groups, the localization of exogenous TDP-43
was then analyzed. Astrocytes with prominent nuclear localization
of transfected WT or M337V TDP43::mApple were grouped and
comparedwith astrocyteswith nuclear-and-cytoplasmic or exclusively
cytoplasmic ﬂuorescence.We noted a strong inﬂuence of expression
levels on TDP-43 localization. Elevated expression levels were
directly related to cytoplasmic mislocalization of TDP-43 (Fig.
4B), as reported (28). However, whereas WT TDP-43 displayed
a dynamic range of localization correlating with expression levels,
M337V TDP-43 showed an inherent bias toward cytoplasmic lo-
calization (Fig. 4C), even at low expression levels (Fig. 4D). These
results conﬁrm that the observed changes in localization of TDP-
43 in iPSC-derived astrocytes are due to the presence of the
M337V mutation on TARDBP.
Survival Analysis on iPSC-Derived Astrocytes. We next asked
whether the accumulation of soluble and cytoplasmic TDP-43 was
accompanied by a reduction in survival as assessed by longitudinal
live ﬂuorescence microscopy as described (11, 28). M337V and
CTRL iPSC-derived astrocytes were transfected with a plasmid
that constitutively expresses enhanced green ﬂuorescent protein
(EGFP) and imaged every 24 h for 10 d. Astrocyte death was
marked by loss of ﬂuorescence or dissolution of the cell itself (Fig.
S4). These criteria are at least as speciﬁc as traditional markers of
particular cell death pathways (29), have the advantage of
detecting all forms of cell death in a single assay, and are therefore
more sensitive. Kaplan–Meier survival analysis was used to plot
cumulative hazard curves depicting the risk of death for M337V
and CTRL astrocytes (Fig. 5A). Cox proportional hazards analysis
was then applied to calculate the relative risk over four in-
dependent experiments, demonstrating a cumulative hazard ratio
(HR) of 2.5 (P = 2 × 10−16; log-rank test) for M337V astrocytes,
indicating a 2.5-fold greater risk of death associated with the TDP-
43 M337V mutation in comparison with CTRLs.
Having established that the M337V mutation reduces the sur-
vival of astrocytes under basal conditions, we then investigated the
mechanism of this toxicity. To determine whether the observed
cell death was due to increased apoptosis, the effect of pan-cas-
pase inhibitor QVD-oph was measured (30). Treatment with the
pan-caspase inhibitor decreased the cumulative HR of M337V
and CTRL astrocytes. QVD-treated CTRL astrocytes showed
a cumulative HR of 0.33 (P = 5.07 × 10−11; log-rank test) com-
pared with the vehicle-treated group. On theM337V background,
the QVD-treated group showed a HR of 0.72 (P = 0.0145; log-
rank test, compared with vehicle-treated CTRL astrocytes),
and the vehicle-treated M337V group showed a HR of 2.66 (P =
8.13 × 10−12; log-rank test, compared with vehicle-treated CTRL
astrocytes) (Fig. 5B). Therefore, the presence of caspase inhib-
itor decreased the risk of death more than threefold in both gen-
otypes. However, when the M337V and WT QVD-treated groups
were compared directly, the M337V astrocytes still displayed a
signiﬁcantly greaterHR thanWT astrocytes (2.19; P= 2.32× 10−7;
log-rank test). The comparison of HRs between M337V and
CTRL astrocytes with QVD or vehicle-only treatment revealed
that caspase inhibition failed to signiﬁcantly lower mutant TDP43-
speciﬁc toxicity (Fig. 5C). Furthermore, survival analysis per-
formed within the transfected astrocyte populations described
earlier revealed that cytoplasmic localization of mutant TDP-43
was associated with a 223% increase in the risk of death (HR =
2.23; P = 0.0002). These results suggest that cytoplasmically mis-
localized M337V TDP-43 signiﬁcantly increases the risk of death
of astrocytes.
Analysis of MN–Astrocyte Cocultures. We next sought to determine
whether mutant M337V astrocytes exert a non-cell-autonomous
toxic effect on MNs, similar to that described for mutant SOD1
rodent astrocytes (1, 8, 9, 31, 32). To this end, we ﬁrst veriﬁed the
utility of survival analysis by longitudinal microscopy for detecting
non-cell-autonomous toxic effects of glia on WT MNs derived
from human iPSCs by coculturing HB9:GFP-transfectedWTMNs
on murine primary astroglia overexpressing either hSOD1WT
or hSOD1G93A. This experiment, as predicted from previous
studies (8), revealed an increased toxic non-cell-autonomous ef-
fect exerted by hSOD1G93A glia compared with hSOD1WT
counterparts onWTMNs (Fig. S5), conﬁrming that a longitudinal
microscopy-based survival analysis approach is capable of de-
tecting astrocyte toxicity in human iPSC-derived MN cocultures.
Fig. 2. Functional characterization of iPSC-derived astrocytes. (A) L-gluta-
mate uptake assay on iPSC-derived astrocytes. iPSC-derived astrocytes cleared
L-glutamate in a time-dependent fashion. ***P < 0.01 (one-way ANOVA). The
uptakewas abolishedby either the absence of sodiumor the presence of 2mM
L-trans-pyrrolidine-2,4-dicarboxylic acid (PDC; both negative CTRLs were run
for 120 min). (B) M337V iPSC-derived astrocytes did not show a signiﬁcant
difference in glutamate clearance rate, compared with CTRL astrocytes (one-
way ANOVA; P > 0.05 for all times considered). (C) Glutamate uptake fold
increase. M337V and CTRL astrocytes were able to clear >75% of L-glutamate
from the medium in 120 min, and uptake was inhibited equally by PDC. No
signiﬁcant difference was observed between the groups. (D) Representative
immunoﬂuorescence panels from synaptogenesis assay. Image shows repre-
sentative neurite segment used for analysis, stainedwith TuJ1 (blue), PSY (red),
and PSD-95 (green; scale bar: 15 μm). (E) iPSC-derived astrocytes signiﬁcantly
promoted synaptogenesiswhen coculturedwithdifferentiatingneurons. ***P
< 0.01 (one-way ANOVA). The increase in synaptogenesis was measured by
scoring the number of PSY+/PSD-95+ puncta in 30-μm neurite segments (co-
culture M337V, 2.4 ± 0.2, SEM; coculture WT, 2.6 ± 0.1, SEM; neurons, 1.00 ±
0.08, SEM). No signiﬁcant difference was observed in the behavior ofM337V
or CTRL iPSC-derived astrocytes. Data represent the average of three in-
dependent experiments, each with two clones of M337V (M337V-1 and -2)
iPSC and two independent CTRL lines (CTRL-1 and -2); data fromdifferent lines
were pooled for graphical presentation. (F) Synaptogenesis assay withM337V
or WT patterned neurons revealed that astrocyte promotion of synapse for-
mation was independent from the genotype of cocultured neurons and that
M337V astrocytes do not exert a negative effect on synaptic formation, even
tomutant neurons. (M337Vneurons onWTastrocytes, 0.90± 0.04, SEM;M337V
neurons on M337V astrocytes, 0.98 ± 0.03 SEM; WT neurons on WT astrocytes,
1.00 ± 0.01 SEM; WT neurons on M337V astrocytes, 1.01 ± 0.02, SEM). (G) iPSC-
derived astrocytes propagate calcium waves to adjacent cells upon mechanical
stimulation. Red outline represents glass bead used for stimulation (200-μm
diameter). Annotation represents time in seconds from stimulation.
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Next, we plated HB9:GFP-transfected iPSC-derived MNs from
both genotypes on a monolayer of either mutant or CTRL iPSC-
derived astrocytes and compared their survival by real-time lon-
gitudinal microscopy as described (11). We ﬁrst tested the effect
of CTRL and mutant astrocyte background on the survival of WT
MN cultures. The cumulative risk of death of WT MNs cultured
on mutant astrocytes was not signiﬁcantly different from that of
WT MNs cultured on WT astrocytes, suggesting that mutant
astrocytes are not toxic to WT MNs (Fig. 5D).
We next determined the survival of mutant M337V MNs in
astrocyte coculture experiments. First, we conﬁrmed that mutant
MNs cultured in isolation demonstrated greater cell-autonomous
vulnerability than CTRL MNs, as previously shown (Fig. 5E)
(11). Using real-time survival analysis, we found that mutant
astrocytes did not exert non-cell-autonomous toxic effects, even
on MNs carrying the M337V TDP-43 mutation (Fig. 5F). In-
deed, when cocultured with astrocytes of either genotype, the
previously observed cell-autonomous vulnerability of isolated
mutant MNs was no longer evident. These results suggest that,
independent of the genetic background of glia, astrocyte co-
culture rescues the survival difference associated with the TDP-
43 M337V mutation in motor neuronal cultures and that iPSC-
derived TDP-43 mutant astrocytes do not exert an in vitro toxic
effect on neurons.
Discussion
The present study describes a platform to study the glial com-
ponent of TDP-43 proteinopathies and its effect on cocultured
neurons. We efﬁciently generated near-homogenous populations
of astrocytes from both CTRL and mutant iPSC lines and
cocultured astrocytes and MNs from different genetic back-
grounds to study potential non-cell-autonomous contributions to
ALS pathology.
We exploited developmental progliogenic signaling pathways
to generate enriched and scalable astroglial progenitors. Propa-
gating NPCs with LIF and EGF, but without FGF2, promoted
glial commitment and expansion and resulted in efﬁcient APC
fate speciﬁcation within 6 wk (33–36). A number of methodolo-
gies derive astroglia from pluripotent cells with varying levels of
function and purity (37–40). The protocol described here achieves
functional astrocyte differentiation without serum supplementa-
tion, presenting a more chemically deﬁned and comparatively
faster alternative to other methods (37). The resulting astroglial
populations have low numbers of neuronal cells (<2%), enabling
the study of astroglial survival, function, and biochemistry in
near-homogenous populations. This homogeneity has a clear
beneﬁt over methodologies that yield glial populations with
greater neuronal differentiation (38) or those that require longer
periods of time. Highly enriched astrocyte populations can also be
generated by prolonged culture (3–9 mo) of neural progenitors
with gradual temporal loss of neurogenic potential, similar to the
neurogenic–gliogenic switch during development (39, 40).
M337V-expressing astrocytes displayed cytoplasmic mis-
localization of TDP-43 with elevated levels of soluble TDP-43
protein, which was not due to an increase in TARDBP mRNA.
There was no increase in detergent-resistant TDP-43 in M337V
mutant astrocytes, but their survival was signiﬁcantly reduced
under basal conditions. The effects on survival were replicated in
CTRL iPSC-derived astrocytes transiently transfected with
M337V mutant TDP-43. These features are comparable to ear-
lier ﬁndings in isolated MN cultures (12) and, together with the
increased stability of mutant TDP-43 reported in isogenic stable
cell lines (41), suggest that the M337V mutation affects TDP-43
Fig. 3. Characterization of TDP-43 in iPSC-derived astrocytes.
(A) qRT-PCR expression analysis of iPSC-derived astrocytes shows
no signiﬁcant difference (P > 0.05 for all pairs; unpaired t test) in
mRNA levels of TARDBP, HDAC6, S100β, or GFAP. Results are
presented as expression fold increase normalized toM337V-1. (B)
Representative Western blot from soluble TDP-43 analysis of
M337V-1, -2, and CTRL-1 astrocytes. (C) Semiquantitative analy-
ses of band signal intensitywas accomplished by using ImageJ on
three independent extractions (M337V-1 mean = 2.0 ± 0.4, SEM;
M337V-2 mean = 1.9 ± 0.4, SEM; CTRL-1 mean = 1.1 ± 0.3, SEM).
**P = 0.003 (repeated measures ANOVA). (D) Representative
confocal images of TDP-43/GFAP immunolabeling used for den-
sitometric analysis. (E) Densitometric quantiﬁcation of TDP-43
localization by confocal microscopy showing a signiﬁcant in-
crease of cytoplasmic TDP-43 in M337V astrocytes; results are
presented asdensitometric signal fold increase normalized to the
CTRL (n = 4 independent experiments). ***P < 0.001.
Fig. 4. Ectopic TDP-43 expression partially reproduces the iPSC phenotype.
(A) Representative images of cytoplasmic and nuclear-only TDP43:mApple-
transfected astrocytes showing the criteria for inclusion of astrocytes in ei-
ther cytoplasmic (Upper) or nuclear (Lower). (B) Analysis of exogenous WT
TDP-43 localization on stratiﬁed relative expression groups. The localization
of WT TDP-43 was signiﬁcantly related to relative expression levels [nuclear
vs. cytoplasmic TDP-43: A, not signiﬁcant (n.s.); B, n.s.; C, n.s.; D, P < 0.05;
E, P < 0.01; F, P < 0.001). Data are pooled from three independent experi-
ments. (C) Analysis of exogenous M337 TDP-43 localization on stratiﬁed rel-
ative expression groups. M337V TDP-43 remained localized mainly to the
cytoplasm regardless of expression level (nuclear vs. cytoplasmic TDP-43: A–F,
P < 0.001). Data are pooled from three independent experiments. (D) Com-
parison of ectopic TDP-43 localization in astrocytes from the lowest relative
expression level groups (group A in B and C). At low expression levels, 73.6 ±
3.3% of astrocytes from the TDP43M337V:mApple group presented mainly or
exclusively cytoplasmic localization of the protein, compared with 44.5 ±
1.6% in the TDP43WT:mApple. **P < 0.01; ***P < 0.001 (one-way ANOVA).
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protein levels via a posttranslational mechanism. It is also of
interest that in the astrocyte populations analyzed, TDP-43 does
not seem to negatively autoregulate its own mRNA, as reported
in established stable lines (42). Mutant astrocytes, unlike mutant
MNs derived from the same lines, do not show increased levels
of detergent-resistant TDP-43 levels. The reason for this ﬁnding
is unclear but suggests different cell-speciﬁc processing of pro-
tein accumulation. Along with accumulation of soluble TDP-43,
mutant astrocytes displayed inherent mislocalization of cyto-
plasmic TDP-43. Increased cytoplasmic TDP-43 levels were not
accompanied by a corresponding depletion of nuclear TDP-43,
further supporting the idea that the additional TDP-43 is due to
increased stability and/or slower clearance. Interestingly, the loss of
TDP-43 nuclear localization has been linked to neuronal de-
generation in TDP-43 proteinopathies in animal models (43) and
cellular systems (44, 45). The absence of TDP-43 nuclear clearance
in M337V iPSC-derived MNs (11) and astrocyte cultures suggests
that loss of nuclear TDP-43 is a later event in the disease process.
Survival analysis of M337V iPSC-derived astrocytes revealed
a signiﬁcantly greater risk of death compared with WT astrocytes
under basal conditions. This result represents a unique report of
cell-autonomous astrocyte toxicity in a mutant iPSC line. These
ﬁndings are consistent with the idea that—at least initially or in
part—reactive astrogliosis observed in ALS might not be simply
a response to neuronal injury but a consequence of direct mu-
tation-mediated astrocyte toxicity. Treatment of mutant and
CTRL astrocytes with pan-caspase inhibitor resulted in a three to
fourfold improvement in cell survival on both genetic back-
grounds. However, when QVD-treated M337V and CTRL
astrocytes were compared directly, they still had a signiﬁcant
difference in their survival, as measured by Cox proportional
hazards analysis. This result suggests that the difference in survival
between M337V and CTRL astrocytes can be attributed to cas-
pase-independent mechanisms. Indirect support for this possibility
is based on the absence of TDP-43 aggregates or signiﬁcant in-
crease of TDP-43 cleavage products in mutant astrocytes, both of
which are associated with caspase activity (46, 47). Although
further studies are required to gain a better understanding of the
mechanism of M337V TDP-43 toxicity on astrocytes, the ectopic
M337V and WT TDP-43 expression studies on isogenic WT
astrocytes reported here demonstrate that the M337V mutation
confers an inherent bias toward cytoplasmic localization. In turn,
the observation that cytoplasmic localization is associated with an
increased risk of death offers an interesting correlation between
the increased cytoplasmic TDP-43 of iPSC-derived astrocytes and
their lower survival, compared with CTRLs. Importantly, these
experiments involved isogenic human astrocytes, so the differ-
ences in mislocalization and toxicity can be attributed speciﬁcally
to the presence of a disease-associated mutation in TDP-43, and
not to potential inﬂuences of differences in genetic background.
Recent in vitro and in vivo models convincingly demonstrated
that astrocytes mediate, at least in part, disease progression in
SOD1 fALS models (1, 8, 9, 31, 32). This ﬁnding, in turn, led to
the concept of non-cell-autonomous neurodegeneration. How-
ever, SOD1 fALS cases, unlike the great majority of sporadic
ALS (sALS) and fALS cases, do not show TDP-43 pathology and
are not therefore classiﬁed as TDP-43 proteinopathies (26).
Understanding whether the TDP-43 mutation carrying astrocytes
have a comparable neurotoxic effect is thus of great interest. Our
previous iPSC-based study showed that the M337V mutation
impairs survival in isolated MNs cultured under basal conditions
(11). In this study, we used the same longitudinal microscopy–
based approach to examine the survival of MNs cocultured
with either M337V or CTRL astrocytes. We detected no sig-
niﬁcant difference in survival of CTRL MNs plated on mutant
astrocytes and equivalent MNs cocultured with CTRL astrocytes.
Importantly, we show, using the same longitudinal microscopy-based
methodology, that murine glia overexpressing hSOD1G93A are toxic
to human iPSC-derived MNs, conﬁrming the ability of this ex-
perimental system to address cellular autonomy in iPSC-based
models as has previously been shown in other xeno-cultures (1, 8).
Notwithstanding the necessity of further validation of our
results in independent human iPSC lines, our results suggest
a potential difference in the consequence of astroglial–neuronal
interaction, at least when modeled under basal conditions in vitro,
between SOD1 and TDP-43 fALS. Interestingly, astrocytes de-
rived from postmortem sALS and SOD1MT fALS patient material
have a non-cell-autonomous toxic effect on mouse ES cell-derived
MNs, extending the concept of toxicity mediated by reactive
astroglia to include sporadic MN disease (9). Reactive astrogliosis
is deﬁned by a number of phenotypic changes in astrocytes (7), and
the extent of mechanistic overlap between the SOD1MT
fALS and sALS astroglia-mediated MN toxicity remains to be
independently conﬁrmed. It is also important to note that non-
cell-autonomous toxicity of human sporadic or, indeed, SOD1MT
iPSC-derived astrocytes has, to date, not been reported. One
potential explanation is that in vitro differentiation of astrocytes
from human iPSCs, as in our study, in the absence of degenerating
neurons does not capture some of the as-yet-uncharacterized
mutation-speciﬁc or more general reactive properties of in vivo
astroglia. Nevertheless, the platform described here is ideal to
Fig. 5. Survival analysis on iPSC-derived astrocytes and MN-astrocyte cocul-
tures. (A) Real-time survival analysis of M337V iPSC-derived astrocytes and
CTRLs. Mutant astrocytes showed increased cumulative risk of death associ-
ated withM337V TDP-43 under basal conditions (HR = 2.5, P = 2 × 10−16; CTRL
taken as baseline; ***P < 0.001). (B) Real-time survival analysis of M337V and
CTRL iPSC-derived astrocytes in the presence of 10 μMQVD-oph. The inhibition
of caspase activation reduced the risk of death in M337V and CTRL astrocytes
(with CTRL+vehicle as a reference, in M337V+vehicle, HR = 2.61, P = 8.13 × 10−
12; M337V+QVD, HR = 0.72, P = 0.0145; CTRL+QVD, HR = 0.33, P = 5.07 × 10−11;
***P< 0.001). (C) Comparison between cumulative HR ofM337V astrocytes in
QVD- and vehicle-treated groups. The error bars represent 95% conﬁdence
intervals. (D) Real-time survival analysis of WT iPSC-derived MNs plated on
either M337V or CTRL iPSC-derived astrocytes. Mutant astrocytes were not
toxic to coculturedWTMNs (withWTMNs onWT astrocytes as a reference, in
WT MNs on M337V astrocytes, HR 0.98; P = 0.68). (E) Real-time survival
analysis of MNs cultured in isolation (n = 3), demonstrating cell-autonomous
toxicity of mutant TDP43 (with WT as a reference, in M337V, HR = 2.02; P =
8.91 × 10−7). (F) Longitudinal analysis of M337V MNs plated on either WT or
M337V astrocytes. Both WT and M337V astrocytes improved the survival of
M337V MNs. M337 astrocytes had no detectable toxicity to cocultured MNs.
All graphs represent pooled data from three independent experiments.
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study both the reactive properties of in vitro-generated astrocytes
and the potential differences between astrocytes generated from
sALS and other fALS iPSC lines.
In conclusion, this study established a platform to address the
biological consequence of somatic mutations on human iPSC-
derived astroglia and to dissect the contribution of glial–neuro-
nal cross-talk in neurodegenerative processes. The application of
the platform to study the non-cell-autonomous component of
TDP-43 proteinopathies and the description of a previously
unrecognized cell-autonomous TDP-43 toxic effect on astrocytes
further highlight the potential of using patient-derived iPSCs to
gain a deeper understanding of the molecular pathogenesis of
neurodegenerative disorders.
Materials and Methods
Generation of Astrocytes from iPSC Lines. Generation of neurospheres from
iPSC lines and their patterning to acquire MN progenitor identity were as
described (11). Neurospheres were mechanically chopped at the beginning
of the enrichment phase and cultured in NSCR EL20 medium for 2–4 wk.
After enrichment, the spheres were propagated in EGF and FGF2 containing
medium and passaged mechanically by chopping them every 2 wk. Details
on establishment of monolayer cultures, dissociation of spheres, media
composition, and functional characterization of the astrocytes are provided
in SI Materials and Methods.
Survival Analysis. For survival analysis, differentiated astrocytes were
plated on 96-well Matrigel-coated plates at a density of 2 × 104 cells per
well and transfected with pGW1-mApple (Fig. 2G) or cotransfected with
pGW1-EGFP and pGW1-TDP43:mApple (Fig. 2 H and I) with Lipofectamine
2000 (Invitrogen). For analysis of cocultures, dissociated MNs from pat-
terned neurospheres were plated on 96-well Matrigel-coated astrocyte
plates after transfection, as described (11). A robotic microscope system
was used to perform the imaging (28, 29). Following transfection, cells
were imaged at 24-h intervals for 10 d, and survival was determined by
using algorithms developed in MatLab and ImageJ. Details on trans-
fections, survival analysis software, and procedures used are provided in
SI Materials and Methods.
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